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Whole-genome sequencing is rapidly transitioning into a tool for clinical research and diagnosis, a shift which brings new challenges for sequence analysis methods. While there has been considerable progress in developing methods to improve germline and somatic small variant calling accuracy in research applications [1] [2] [3] [4] [5] [6] , such methods can be further improved in many respects for the clinical wholegenome sequencing scenario. These improvements include reducing the compute cost/turn-around time of whole-genome analysis, further increasing indel calling accuracy, automating parameter tuning without expert user intervention, and reducing multiple indicators of call quality to a single confidence score for variant prioritization. Here we describe Strelka2, a variant calling method building upon the innovative Strelka somatic variant caller 7 , to improve upon these aspects of variant calling for both germline and somatic analysis. We demonstrate that Strelka2 is both more accurate and substantially faster when compared to current best-in-class small variant calling methods.
Strelka2 germline and somatic analyses share a common series of high-level stages, including parameter estimation from sample data, candidate variant discovery, realignment, variant probability inference, and empirical re-scoring/filtration. The composition of these steps is described in more detail for each type of analysis in Supplementary Fig. 1 .
Strelka2's germline analysis introduces a novel step to adaptively estimate indel error rates from preliminary allele counts in each sample, using a mixture model to estimate both indel variant mutation rates and indel noise rates from a set of error processes (Supplementary Fig. 2 ). This mixture approach mitigates the impact of context-specific indel error rate variation on variant call accuracy and obviates the need to specify a prior set of common population variants.
Similar to previous work 2,3,5,6 , Strelka2's germline analysis models haplotypes to provide read-backed variant phasing and reduce the impact of sequencing noise, incorrect read mapping and inconsistent alignment. Strelka2's haplotype model uses an efficient tiered scheme for haplotype discovery, combining the advantages of a simple model based on input read alignments 3 , and a more complex model using local assembly 2, 5, 6 , where the appropriate method is selected based on the properties of each variant locus. This tiered haplotype modeling approach is essential to optimize runtime without precision loss. The haplotype model also introduces a novel heuristic filter for sequencer phasing noise, improving the caller's robustness to a wider variety of potential sequencing artifacts.
In Strelka2's germline and somatic variant probability models, additional runtime improvements are made in the computation of read likelihoods by enumerating a small number of candidate alignments and using the maximum alignment-specific likelihood to approximate the marginal likelihood, avoiding the computational cost of a complete implementation such as a pair HMM 8 . Within the somatic variant probability model, the original Strelka method has been redesigned with a further novel innovation to account for contamination of tumor cells in the matched normal sample such that somatic recall is improved, especially for liquid tumor analysis. Consistent with the emphasis on automated sample adaption in Strelka2, the liquid tumor model is an expansion of the model's state space applied to all cases, and thus does not require prior knowledge of the normal sample contamination level.
For both germline and somatic calling workflows, the variant probability model is supplemented by a final empirical variant scoring (EVS) step, motivated in part by machine learning-based variant classification approaches 9, 10 . This step uses a random forest model trained on numerous features indicative of call quality to improve precision by accounting for error phenomena that are not adequately represented in the generative variant probability model. Strelka2's EVS models are pretrained on data from a variety of sequencing conditions to improve robustness, and produce a single aggregate score which can be used to set application-specific precision levels or prioritize variants for follow-up.
To assess its germline calling performance, we ran Strelka2 on the recent PrecisionFDA Consistency and Truth challenge data 11 and compared its results with the challenge submissions ( Fig. 1a) . This comparison shows that for the noisier sequence datasets in the Consistency challenge, Strelka2's indel accuracy is remarkably higher than the winning challenge submissions, improving upon the indel F-score of the best challenge submission by 3.1%. For the other two Truth challenge data sets with lower sequencing noise, Strelka2 still improves upon the best challenge submission with an indel F-score improvement of 0.08%. For single nucleotide variants, Strelka2 gave competitive results within only 0.05% -0.1% of the best submissions ( Supplementary Fig. 3 ). These results are striking when considering that all Strelka2 analyses used default parameters, a single read mapper and no input from population variant databases, whereas the top results of the PrecisionFDA challenge were obtained using pipelines specially trained for the challenge data or by combining results from multiple read mappers and variant callers.
To assess runtime, we benchmarked Strelka2 against a recently released high-speed GATK Haplotyper reimplementation (Sentieon DNAseq Haplotyper) that is over 10x faster than the original HaplotypeCaller 12 . On the PrecisionFDA datasets discussed above, Strelka2 was 2.1 times faster than Sentieon DNAseq Haplotyper on average on the same computer hardware while also outperforming it in accuracy, with an average F-score improvement of 2.1% for indels and 0.29% for SNVs ( Fig. 1) .
We evaluated Strelka2's somatic variant calling accuracy by mixing sequencing data of unrelated individuals to simulate impure tumor and matched normal samples. For this purpose, we used NA12878 and NA12877 to represent, respectively, the tumor and normal samples. We simulated datasets with tumor purities of 20%, 50%, and 80%, and one matched normal sample with 90% purity. The truth set for these evaluations were the Platinum Genomes 13 variants in NA12878 where the corresponding NA12877 genotype is homozygous reference. Using the in-silico mixtures, we compared the somatic variant call accuracy of Strelka2 with a recent high-speed MuTect2 4 reimplementation (Sentieon TNseq TNhaplotyper). As summarized in Fig. 2a , Strelka2 shows substantially higher precision than TNhaplotyper at all recall thresholds over all test datasets, with an average F-score improvement of 29% for SNVs and 35% for indels. We note in particular Strelka2's superior tolerance to normal sample impurity, reflecting updates in Strelka2's somatic calling model to better support such contamination in liquid and late-stage solid tumor analyses. This was tested using the 80% purity tumor sample and noting the impact on somatic F-score when the normal sample purity changed from 100% to 90%. Strikingly, for TNhaplotyper the F-score dropped from 77% to 30% for SNVs and from 47% to 17% for indels. For Strelka2, the impact was substantially smaller, changing from 96% to 90% for SNVs and from 82% to 65% for indels.
We assessed runtime for Strelka2's somatic analysis and found that, as for the germline analysis, Strelka2 is substantially faster than available alternatives. For the above somatic analysis using in-silico sample mixtures, Strelka2 demonstrated an average runtime advantage of 3.2x over TNhaplotyper, which itself is over 10x faster than the original MuTect2 implementation ( Fig. 2b) 12 .
In the above analyses, we demonstrate the effectiveness of multiple statistical modeling and algorithmic innovations in Strelka2, resulting in remarkable improvements to accuracy and runtime for both germline and somatic calling. We reiterate that results were generated with default method settings appropriate for factory-scale analysis, not requiring human intervention to parameterize or connect complex sequences of tools. All results use only a reference genome and one alignment file per sample as input. Additionally, no prior variant databases are used in the calling process, reducing the potential for bias against rare variants or ancestry-dependent artifacts.
Improvements to Strelka2 continue in several areas. We have already generalized Strelka2's germline analysis for RNA-Seq (not described here) and efforts are ongoing to improve mitochondrial variant calling and to integrate with structural variant predictions. Generalization of Strelka2's adaptive indel error estimation methods to mitigate the impact of context-sensitive base-calling errors on SNV calling has been prototyped and shows promise. The application of these techniques to somatic variant analysis, while considerably more challenging, could substantially improve our ability to call very lowfrequency variants. We see such adaptive parameterization improvements as complementing rather than competing with recent trends emphasizing a greater focus on empirical machine learning approaches to variant calling. Indeed, the improvement of generative sequencing error models to more closely represent the sample data should sharpen the effectiveness of downstream machine-learning approaches by reducing confounding error terms, a circumstance we have already leveraged to improve the accuracy of Strelka2.
Online Methods
Parameter estimation. Chromosome depth estimation. An initial step in all workflows is the rapid estimation of the sequencing depth for each chromosome, which for somatic analysis is computed only for the normal sample.
Indel error model. Indel sequencing errors are modeled in the variant calling steps below as a process which occurs independently in each read, with some fixed probability of an indel error occurring as a function of the short tandem repeat (STR) context ( Supplementary Fig. 2 ). For germline variant calling, these error probabilities are estimated from the sequencing data of each input sample in two steps. First, mapped sequencing data are analyzed at a subset of sites across the genome to produce error counts for various sequencing contexts. Second, the counts are used to estimate the parameters of interest. For somatic variant calling, a simpler non-adaptive approach is used in which the indel error parameters are pre-set based on empirical observation of indel calling performance and error rates are a function of the homopolymer context length r only.
Error counting. At every counted site in the genome, the number of reads supporting each potential allele are accumulated by context. The counting process uses a read realignment strategy similar to that used by the variant calling process explained below.
Each STR tract with pattern size s and repeat count r at locus is counted as a single observation for the Error rate estimation. Every indel locus is modeled as belonging to either a clean state (generating essentially no indel errors) or a noisy state (generating indel errors independently across reads according to a set of error probabilities to be estimated), with the overall error probabilities being drawn from the resulting two-state mixture model. The allele counts, in turn, are modeled as drawn from a mixture over possible genotypes, with the genotype-specific distributions being multinomial for homozygous genotypes and mixtures of two multinomials for heterozygous genotypes. The multinomial distributions are governed by the local coverage = ∑ ( ) and by rates selected from the vector of available error rates according to the alleles 1 h and 2 h comprising the genotype ( Supplementary Fig. 2a ).
For every STR context { } r s, we define the following parameters. Together, the parameters comprise We fix all of the clean-state error probabilities to a small constant value: When ℎ = ℎ (homref or homalt genotype), the likelihood of the count vector is:
is the corresponding multinomial coefficient. Since this coefficient does not depend on any model parameters, it is ignored during parameter estimation.
When ℎ ≠ ℎ (het or hetalt genotype), the likelihood is:
, , | ( To reduce the number of estimated parameters, we model homopolymer repeats (
as log-linear in r, allowing us to estimate values for ( , ) ∈ -(1,1), (1, 2) , (1, 16) , (2, 2) , (2, 9) 1 and interpolate between these values. The values at (1, 16) and (2, 9) are used for 16 > r or 9 > r respectively.
When using the estimated parameters for variant calling ( Supplementary Fig. 2b, described below) , we assume that all sites at which candidate haplotypes have been generated belong to the noisy state, so that the mixture model formulation is not needed. For this reason, only the noisy-state error probabilities are passed on for downstream use. We also fix the insertion and deletion error rates to be used for calling to the geometric mean of the insertion and deletion estimates for each STR context. and d c ⋅ ≥ 0.2 . Afterwards, nearby variant loci are clustered if they are no more than 13 bases of each other. For the clusters including two or more variant loci, the cluster region is further extended to the surrounding loci so that the first and last locus are not within a homopolymer or STR region. This extension is needed because alignments that do not fully span such repeats are often erroneous and relying on them may lead to generating incorrect haplotypes. To accomplish this, we detect anchor loci that are not variant loci and also do not belong to a homopolymer (of lengths no less than 3) or STR (of repeat unit lengths between 2 and 50). Given a cluster of variant loci, the active region is created between the closest anchor loci before and after the first and last variant loci.
Haplotype generation. Given an active region of size of 250 or smaller, haplotype generation is attempted using either the alignment-based or assembly-based model. The decision is made based on the fraction of reads that fully cover the active region (called covering reads): the assembly-based model is used if fewer than 65% of all reads that overlap with an active region are covering reads.
If the alignment-based model is selected, then for each covering read, the segment aligned to the active region is extracted as a candidate haplotype. If a candidate haplotype s is extracted from a read r , we call r a supporting read of s , such that for each candidate haplotype s a set of supporting reads is identified.
If the assembly-based model is selected, local de novo assembly is run using a de Bruijn graph approach similar to that described in TIGRA 14 . This expansion allows the identification of assembled contigs which span the full locus by identifying those that share the same prefix (reference segment at ] , [ i i′ ; denoted by a prefix anchor) and suffix (reference segment at ] , [ j j ′ ; denoted by a suffix anchor). All the reads that (fully or partially) overlap with the expanded active region are used as input to the assembly procedure. After assembly is finished, only the contigs including both prefix and suffix anchors are selected and the prefix and suffix anchors are removed. Each such contig becomes a candidate haplotype and the set of reads supporting the contig is identified.
Haplotype generation for an active region is considered unsuccessful if the assembly procedure is selected and assembly is unable to generate at least one non-reference candidate haplotype. If haplotype generation does not succeed, indel candidates can still be generated as detailed below without the benefit of haplotyping.
Haplotype filtration. If haplotype generation is successful (using either alignment-based or assemblybased methods), candidate haplotypes are ranked by decreasing read support; those with fewer than 3 supporting reads or ranking below the top x , for x the expected sample ploidy (assumed to be diploid in the current procedure), are excluded from further processing. If there is more than one remaining haplotype, an additional filtration step is applied to reduce candidates produced by phasing noise in the sequencing process across a homopolymer. Primitive allele discovery. After filtration, the remaining candidate haplotypes are aligned to the reference and primitive alleles (SNVs and indels of size 50 and smaller) are annotated as discovered. These discovered primitive alleles are used to improve SNV and indel calling in downstream procedures.
Indel candidacy. Strelka2 uses indel candidacy as a preliminary filter to eliminate indel observations likely to have been generated by error processes. Candidate indels are considered during read realignment and indel genotyping in all samples. To become a candidate, an indel variant must minimally have 2 reads supporting it in at least one sample. If haplotype modeling is enabled, a candidate indel belonging to an active region where haplotyping was successful must also have been discovered through haplotype alignment in at least one sample. If an indel observation satisfies these conditions, Strelka2 evaluates its candidacy status using a one-sided binomial exact test, with the null hypothesis being that the indel coverage is generated by indel error processes. The indel is considered a candidate variant if the resulting p-value is below
Read realignment and variant probability inference. Read realignment. Following the discovery of candidate alleles, reads are realigned to these candidates. This realignment step has two primary functions. The first is to generate the set of most likely alignments under the assumption that the read was generated by a particular candidate haplotype. Such alignments are used to assess the read's relative support for different indel alleles. The second function is to create a single representative alignment to use for SNV calling.
The alignment search uses a starting alignment provided by the input alignment file, as well as a set of intersecting candidate indels. If the read intersects at least one candidate indel, a set of alignments is built from the starting alignment by recursively toggling indels from the candidate set. Each toggling operation produces three alignments: the input alignment itself, and two alignments constructed by adding or removing the indel in question such that the input alignment is unchanged (1) to the left or (2) to the right of the indel. For efficiency, the search recursion is limited to depth 5. Germline Variant Phasing. As previously noted, Strelka2 defines an active region around dense variants and infers 2 haplotypes for the region. These haplotypes are used to phase SNVs and indels within the same active region. The phasing is conducted after scoring and genotyping. For each heterozygous variant belonging to an active region, Strelka2 matches the variant alleles to the active region haplotype to appropriately phase the genotype allele order. 
Here D refers to the sequencing data from both samples. The likelihood term above is computed by integrating over sample-specific allele frequencies ).
Somatic variant calls are reported jointly with associated calls for the normal sample. For this, we use the joint probability of somatic variation and the maximum likelihood normal sample genotype:
Given the expected rate of variants between two unrelated haplotypes θ , the normal sample genotype prior ) ( n G P 
where γ is set to 4 10 − for SNVs and 
Here, τ and δ represent contamination tolerance terms, ). ,
The likelihood for an individual read can be expressed in terms of likelihoods conditioned on each of the potential generating haplotypes:
is the probability of an individual read d , given its associated basecall qualities q and a generating haplotype h . In a complete probabilistic implementation (e.g. using a pair HMM), this likelihood would be computed by summing over all possible pairwise alignments A in which d is aligned to h . Strelka2 saves computation by enumerating a small number of candidate alignments and using the maximum alignment-specific likelihood to approximate the marginal likelihood:
The alignment-specific likelihood scores can be factorized as follows: where the product is taken over all positions k at which a gap is opened and reversion to reference refers to indels that result in the reference allele being generated even though the generating haplotype contained a non-reference allele at position k . To compensate for reference-bias in the alignment process, Empirical scoring and filtration. The variant calling models (both germline and somatic) provide sufficiently accurate representations of the biology and sequencing process to produce an initial variant probability inference. However, there is additional information not used by the models which is nonetheless predictive of call accuracy. As a final step in the variant calling process, such additional information is extracted as a set of predictive features and used in combination with the probability calculated by the variant calling model to improve call precision. This is done by the Empirical Variant Scoring (EVS) model, a supervised random forest classifier trained on labeled data from sequencing runs performed under a variety of conditions (different sequencers, sample preparation, and coverage). The EVS model provides an aggregate quality score for each variant and allows for convenient exploration of the precision-recall curve.
For each of germline and somatic variant calling, there are two separate feature sets and trained random forest models: one for SNVs and one for indels. In contrast to dynamic re-scoring systems such as the GATK VQSR procedure 9 , the EVS models are pre-trained, allowing Strelka2 to avoid the runtime cost, instability and population variant data requirement of a dynamic approach. When the EVS model is not used, simple cutoffs are applied to a set of features (not necessarily the same set used by EVS) to less precisely filter out potentially problematic calls. For details on EVS training and the full lists of EVS and hard-filter features, refer to Supplementary Note 2. PrecisionFDA submissions and stars denote the submissions with the best F-scores. For all 4 datasets from these challenges, we mapped each sample using bwa-mem, and ran Strelka2 on default settings. We then compared results against the latest genome in a bottle truth set 15 
